Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 25.46M 22.13M 20.66M 18.97M 35.76M 2.43B 36.38M 244M 95.4M 1.21B 95.64M 93.52M 3.99B P/E 2026 *
-0.96x
P/E 2027 * -1.45x
Enterprise Value 25.46M 22.13M 20.66M 18.97M 35.76M 2.43B 36.38M 244M 95.4M 1.21B 95.64M 93.52M 3.99B EV / Sales 2026 *
-
EV / Sales 2027 * 1.97x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-29 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-29 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-30 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
02-13 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day-0.56%
1 week-7.21%
Current month-0.56%
1 month-15.71%
3 months-26.40%
6 months-25.08%
Current year-39.80%
1 week 0.71
Extreme 0.708
0.74
1 month 0.71
Extreme 0.708
0.9
Current year 0.71
Extreme 0.708
1.25
1 year 0.71
Extreme 0.708
1.5
3 years 0.71
Extreme 0.708
9.8
5 years 0.71
Extreme 0.708
19.8
10 years 0.71
Extreme 0.708
57.33
Manager TitleAgeSince
Chief Executive Officer 62 08/06/2017
Chief Tech/Sci/R&D Officer - 31/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 31/12/2007
Chairman 62 30/09/2013
Director/Board Member 68 07/11/2013
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-7.21% - - 26.26M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +0.99%-1.88%+38.83%+165.58% 25.98B
Weighted average by Cap. +0.14%-1.70%+31.71%+123.13%

Financials

2026 *2027 *
Net sales - 12.93M 11.23M 10.49M 9.63M 18.16M 1.23B 18.47M 124M 48.44M 614M 48.56M 47.48M 2.03B
Net income -28.5M -24.77M -23.12M -21.23M -40.03M -2.72B -40.73M -273M -107M -1.35B -107M -105M -4.47B -23.27M -20.22M -18.88M -17.33M -32.68M -2.22B -33.25M -223M -87.19M -1.11B -87.4M -85.46M -3.65B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change
03/08/26 €0.7080 -0.56%
31/07/26 €0.7120 -0.14%
30/07/26 €0.7130 -3.65%
29/07/26 €0.7400 +0.82%
28/07/26 €0.7340 -0.94%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8115USD
Average target price
5.000USD
Spread / Average Target
+516.14%

Quarterly revenue - Rate of surprise